Condition
Primary Amyloidosis of Light Chain Type
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed3
Terminated1
Withdrawn1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03923920Completed
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
NCT03886155Completed
Cardiac Amyloidosis Screening at Trigger Finger Release
NCT01511263Phase 2TerminatedPrimary
Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
NCT01531751Phase 2WithdrawnPrimary
High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
NCT01510613Phase 2CompletedPrimary
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Showing all 5 trials